Claro Advisors’s Kindred Biosciences, Inc. KIN Stock Holding History

Claro Advisors’s Portfolio KIN Stock Details KIN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-111	Closed	-$2K	–	1038
2018 Q4	$2K	Buy	+111	New	+$1.4K	﹤0.01%	963

Other funds holding KIN

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Claro Advisors's KIN Position: Q1 2019 in Review

Claro Advisors sold out of Kindred Biosciences, Inc. (KIN) in Q1 2019, closing a stake of 111 shares — an estimated $2K sold.

Claro Advisors first reported a position in KIN in Q4 2018 and held it in 1 quarter. The position peaked at $2K in Q4 2018. 75 funds tracked by Wall St. Rank hold KIN as of Q1 2019.

Claro Advisors reported no remaining Kindred Biosciences, Inc. position as of Q1 2019 after selling out during the quarter.
Claro Advisors sold 111 Kindred Biosciences, Inc. shares in Q1 2019, an estimated $2K.
Claro Advisors first reported a position in Kindred Biosciences, Inc. in Q4 2018 and held it in 1 quarter.
Claro Advisors's Kindred Biosciences, Inc. position peaked at $2K in Q4 2018.
75 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q1 2019.

Based on Claro Advisors's 13F filing for Q1 2019, filed 10 May 2019.